Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Capecitabine
All products: general benefit
Ach-Capecitabine · DIN 02426757 · 150 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ach-Capecitabine · DIN 02426757
Manufacturer: Accord Healthcare Inc.; listing date 2015-02-26
Health Canada: Marketed since 2014-09-19 · brand ACH-CAPECITABINE · ATC L01BC06 CAPECITABINE · form Tablet · route Oral · ingredients CAPECITABINE 150 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAch-Capecitabine: Formulary list price $0.46 per unit (the source does not state the unit; exact figure $0.4575). What the ministry pays, not the patient.
Ministry pays: $0.4575 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02426757)
Source record
DIN 02426757: Ach-Capecitabine
Raw flags: sec3=Y
Item: 100000136; group id 149; item number 0252; lccId None; manufacturer id ACH
Source form: Tab; strength: 150mg
Recorded listing: General benefit
Source prices (unrounded): $0.4575; ministry $0.4575
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02426757
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91132
Interchangeable products
Capecitabine · DIN 02514982 · $0.4575
Capecitabine · DIN 02519879 · $0.4575
Sandoz Capecitabine · DIN 02421917 · $0.4575
Taro-Capecitabine · DIN 02457490 · $0.4575
Teva-Capecitabine · DIN 02400022 · $0.4575
Xeloda · DIN 02238453 · $0.4575
Shortage status: resolved shortage (ended December 8, 2017); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02426757
Shortage record checked October 6, 2026
Capecitabine · DIN 02514982 · 150 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Capecitabine · DIN 02514982
Manufacturer: Sanis Health Inc.; listing date 2021-12-17
Health Canada: Marketed since 2021-10-22 · brand CAPECITABINE · ATC L01BC06 CAPECITABINE · form Tablet · route Oral · ingredients CAPECITABINE 150 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCapecitabine: Formulary list price $0.46 per unit (the source does not state the unit; exact figure $0.4575). What the ministry pays, not the patient.
Ministry pays: $0.4575 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02514982)
Source record
DIN 02514982: Capecitabine
Raw flags: sec3=Y
Item: 100000136; group id 149; item number 0252; lccId None; manufacturer id SAI
Source form: Tab; strength: 150mg
Recorded listing: General benefit
Source prices (unrounded): $0.4575; ministry $0.4575
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02514982
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100438
Interchangeable products
Ach-Capecitabine · DIN 02426757 · $0.4575
Capecitabine · DIN 02519879 · $0.4575
Sandoz Capecitabine · DIN 02421917 · $0.4575
Taro-Capecitabine · DIN 02457490 · $0.4575
Teva-Capecitabine · DIN 02400022 · $0.4575
Xeloda · DIN 02238453 · $0.4575
Shortage status: active shortage (reported August 24, 2026, estimated to end October 9, 2026, last updated October 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02514982
Shortage record checked October 6, 2026
Capecitabine · DIN 02519879 · 150 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Capecitabine · DIN 02519879
Manufacturer: Jamp Pharma Corporation; listing date 2022-07-29
Health Canada: Marketed since 2022-06-15 · brand CAPECITABINE · ATC L01BC06 CAPECITABINE · form Tablet · route Oral · ingredients CAPECITABINE 150 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCapecitabine: Formulary list price $0.46 per unit (the source does not state the unit; exact figure $0.4575). What the ministry pays, not the patient.
Ministry pays: $0.4575 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02519879)
Source record
DIN 02519879: Capecitabine
Raw flags: sec3=Y
Item: 100000136; group id 149; item number 0252; lccId None; manufacturer id JPC
Source form: Tab; strength: 150mg
Recorded listing: General benefit
Source prices (unrounded): $0.4575; ministry $0.4575
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02519879
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100911
Interchangeable products
Ach-Capecitabine · DIN 02426757 · $0.4575
Capecitabine · DIN 02514982 · $0.4575
Sandoz Capecitabine · DIN 02421917 · $0.4575
Taro-Capecitabine · DIN 02457490 · $0.4575
Teva-Capecitabine · DIN 02400022 · $0.4575
Xeloda · DIN 02238453 · $0.4575
Shortage status: resolved shortage (ended April 26, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02519879
Shortage record checked October 6, 2026
Sandoz Capecitabine · DIN 02421917 · 150 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Capecitabine · DIN 02421917
Manufacturer: Sandoz Canada Inc.; listing date 2014-12-18
Health Canada: Marketed since 2014-07-23 · brand SANDOZ CAPECITABINE · ATC L01BC06 CAPECITABINE · form Tablet · route Oral · ingredients CAPECITABINE 150 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Capecitabine: Formulary list price $0.46 per unit (the source does not state the unit; exact figure $0.4575). What the ministry pays, not the patient.
Ministry pays: $0.4575 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02421917)
Source record
DIN 02421917: Sandoz Capecitabine
Raw flags: sec3=Y
Item: 100000136; group id 149; item number 0252; lccId None; manufacturer id SDZ
Source form: Tab; strength: 150mg
Recorded listing: General benefit
Source prices (unrounded): $0.4575; ministry $0.4575
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02421917
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90661
Interchangeable products
Ach-Capecitabine · DIN 02426757 · $0.4575
Capecitabine · DIN 02514982 · $0.4575
Capecitabine · DIN 02519879 · $0.4575
Taro-Capecitabine · DIN 02457490 · $0.4575
Teva-Capecitabine · DIN 02400022 · $0.4575
Xeloda · DIN 02238453 · $0.4575
Shortage status: resolved shortage (ended December 16, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02421917
Shortage record checked October 6, 2026
Taro-Capecitabine · DIN 02457490 · 150 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Taro-Capecitabine · DIN 02457490
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2017-10-30
Health Canada: Marketed since 2017-08-31 · brand TARO-CAPECITABINE · ATC L01BC06 CAPECITABINE · form Tablet · route Oral · ingredients CAPECITABINE 150 MG · company Taro pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTaro-Capecitabine: Formulary list price $0.46 per unit (the source does not state the unit; exact figure $0.4575). What the ministry pays, not the patient.
Ministry pays: $0.4575 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02457490)
Source record
DIN 02457490: Taro-Capecitabine
Raw flags: sec3=Y
Item: 100000136; group id 149; item number 0252; lccId None; manufacturer id TAR
Source form: Tab; strength: 150mg
Recorded listing: General benefit
Source prices (unrounded): $0.4575; ministry $0.4575
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02457490
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94454
Interchangeable products
Ach-Capecitabine · DIN 02426757 · $0.4575
Capecitabine · DIN 02514982 · $0.4575
Capecitabine · DIN 02519879 · $0.4575
Sandoz Capecitabine · DIN 02421917 · $0.4575
Teva-Capecitabine · DIN 02400022 · $0.4575
Xeloda · DIN 02238453 · $0.4575
Shortage status: resolved shortage (ended December 18, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02457490
Shortage record checked October 6, 2026
Ach-Capecitabine · DIN 02426765 · 500 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ach-Capecitabine · DIN 02426765
Manufacturer: Accord Healthcare Inc.; listing date 2015-02-26
Health Canada: Marketed since 2014-09-19 · brand ACH-CAPECITABINE · ATC L01BC06 CAPECITABINE · form Tablet · route Oral · ingredients CAPECITABINE 500 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAch-Capecitabine: Formulary list price $1.53 per unit (the source does not state the unit; exact figure $1.5250). What the ministry pays, not the patient.
Ministry pays: $1.5250 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02426765)
Source record
DIN 02426765: Ach-Capecitabine
Raw flags: sec3=Y
Item: 100000137; group id 149; item number 0253; lccId None; manufacturer id ACH
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $1.5250; ministry $1.5250
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02426765
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91133
Interchangeable products
Capecitabine · DIN 02514990 · $1.5250
Capecitabine · DIN 02519887 · $1.5250
Mint-Capecitabine · DIN 02508028 · $1.5250
Sandoz Capecitabine · DIN 02421925 · $1.5250
Taro-Capecitabine · DIN 02457504 · $1.5250
Teva-Capecitabine · DIN 02400030 · $1.5250
Xeloda · DIN 02238454 · $1.5250
Shortage status: resolved shortage (ended December 8, 2017); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02426765
Shortage record checked October 6, 2026
Capecitabine · DIN 02514990 · 500 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Capecitabine · DIN 02514990
Manufacturer: Sanis Health Inc.; listing date 2021-12-17
Health Canada: Marketed since 2021-10-22 · brand CAPECITABINE · ATC L01BC06 CAPECITABINE · form Tablet · route Oral · ingredients CAPECITABINE 500 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCapecitabine: Formulary list price $1.53 per unit (the source does not state the unit; exact figure $1.5250). What the ministry pays, not the patient.
Ministry pays: $1.5250 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02514990)
Source record
DIN 02514990: Capecitabine
Raw flags: sec3=Y
Item: 100000137; group id 149; item number 0253; lccId None; manufacturer id SAI
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $1.5250; ministry $1.5250
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02514990
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100439
Interchangeable products
Ach-Capecitabine · DIN 02426765 · $1.5250
Capecitabine · DIN 02519887 · $1.5250
Mint-Capecitabine · DIN 02508028 · $1.5250
Sandoz Capecitabine · DIN 02421925 · $1.5250
Taro-Capecitabine · DIN 02457504 · $1.5250
Teva-Capecitabine · DIN 02400030 · $1.5250
Xeloda · DIN 02238454 · $1.5250
Shortage status: resolved shortage (ended September 3, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02514990
Shortage record checked October 6, 2026
Capecitabine · DIN 02519887 · 500 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Capecitabine · DIN 02519887
Manufacturer: Jamp Pharma Corporation; listing date 2022-07-29
Health Canada: Marketed since 2022-06-16 · brand CAPECITABINE · ATC L01BC06 CAPECITABINE · form Tablet · route Oral · ingredients CAPECITABINE 500 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCapecitabine: Formulary list price $1.53 per unit (the source does not state the unit; exact figure $1.5250). What the ministry pays, not the patient.
Ministry pays: $1.5250 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02519887)
Source record
DIN 02519887: Capecitabine
Raw flags: sec3=Y
Item: 100000137; group id 149; item number 0253; lccId None; manufacturer id JPC
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $1.5250; ministry $1.5250
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02519887
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100912
Interchangeable products
Ach-Capecitabine · DIN 02426765 · $1.5250
Capecitabine · DIN 02514990 · $1.5250
Mint-Capecitabine · DIN 02508028 · $1.5250
Sandoz Capecitabine · DIN 02421925 · $1.5250
Taro-Capecitabine · DIN 02457504 · $1.5250
Teva-Capecitabine · DIN 02400030 · $1.5250
Xeloda · DIN 02238454 · $1.5250
Shortage status: resolved shortage (ended August 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02519887
Shortage record checked October 6, 2026
Mint-Capecitabine · DIN 02508028 · 500 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Capecitabine · DIN 02508028
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2021-12-17
Health Canada: Marketed since 2021-10-05 · brand MINT-CAPECITABINE · ATC L01BC06 CAPECITABINE · form Tablet · route Oral · ingredients CAPECITABINE 500 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Capecitabine: Formulary list price $1.53 per unit (the source does not state the unit; exact figure $1.5250). What the ministry pays, not the patient.
Ministry pays: $1.5250 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02508028)
Source record
DIN 02508028: Mint-Capecitabine
Raw flags: sec3=Y
Item: 100000137; group id 149; item number 0253; lccId None; manufacturer id MIN
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $1.5250; ministry $1.5250
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02508028
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99738
Interchangeable products
Ach-Capecitabine · DIN 02426765 · $1.5250
Capecitabine · DIN 02514990 · $1.5250
Capecitabine · DIN 02519887 · $1.5250
Sandoz Capecitabine · DIN 02421925 · $1.5250
Taro-Capecitabine · DIN 02457504 · $1.5250
Teva-Capecitabine · DIN 02400030 · $1.5250
Xeloda · DIN 02238454 · $1.5250
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02508028
Shortage record checked October 6, 2026
Sandoz Capecitabine · DIN 02421925 · 500 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Capecitabine · DIN 02421925
Manufacturer: Sandoz Canada Inc.; listing date 2014-12-18
Health Canada: Marketed since 2014-07-23 · brand SANDOZ CAPECITABINE · ATC L01BC06 CAPECITABINE · form Tablet · route Oral · ingredients CAPECITABINE 500 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Capecitabine: Formulary list price $1.53 per unit (the source does not state the unit; exact figure $1.5250). What the ministry pays, not the patient.
Ministry pays: $1.5250 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02421925)
Source record
DIN 02421925: Sandoz Capecitabine
Raw flags: sec3=Y
Item: 100000137; group id 149; item number 0253; lccId None; manufacturer id SDZ
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $1.5250; ministry $1.5250
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02421925
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90662
Interchangeable products
Ach-Capecitabine · DIN 02426765 · $1.5250
Capecitabine · DIN 02514990 · $1.5250
Capecitabine · DIN 02519887 · $1.5250
Mint-Capecitabine · DIN 02508028 · $1.5250
Taro-Capecitabine · DIN 02457504 · $1.5250
Teva-Capecitabine · DIN 02400030 · $1.5250
Xeloda · DIN 02238454 · $1.5250
Shortage status: resolved shortage (ended January 8, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02421925
Shortage record checked October 6, 2026
Taro-Capecitabine · DIN 02457504 · 500 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Taro-Capecitabine · DIN 02457504
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2017-10-30
Health Canada: Marketed since 2017-08-31 · brand TARO-CAPECITABINE · ATC L01BC06 CAPECITABINE · form Tablet · route Oral · ingredients CAPECITABINE 500 MG · company Taro pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTaro-Capecitabine: Formulary list price $1.53 per unit (the source does not state the unit; exact figure $1.5250). What the ministry pays, not the patient.
Ministry pays: $1.5250 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02457504)
Source record
DIN 02457504: Taro-Capecitabine
Raw flags: sec3=Y
Item: 100000137; group id 149; item number 0253; lccId None; manufacturer id TAR
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $1.5250; ministry $1.5250
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02457504
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94455
Interchangeable products
Ach-Capecitabine · DIN 02426765 · $1.5250
Capecitabine · DIN 02514990 · $1.5250
Capecitabine · DIN 02519887 · $1.5250
Mint-Capecitabine · DIN 02508028 · $1.5250
Sandoz Capecitabine · DIN 02421925 · $1.5250
Teva-Capecitabine · DIN 02400030 · $1.5250
Xeloda · DIN 02238454 · $1.5250
Shortage status: resolved shortage (ended November 5, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02457504
Shortage record checked October 6, 2026
Teva-Capecitabine · DIN 02400022 · 150 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2022-03-16 — choose a marketed DIN from the same-category list.Discontinued March 16, 2022 · checked November 18, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-03-16 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-03-16 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Capecitabine · DIN 02400022
Manufacturer: Teva Canada Limited; listing date 2013-10-31
Health Canada: Cancelled post market since 2022-03-16 · brand TEVA-CAPECITABINE · ATC L01BC06 CAPECITABINE · form Tablet · route Oral · ingredients CAPECITABINE 150 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Capecitabine: Formulary list price $0.46 per unit (the source does not state the unit; exact figure $0.4575). What the ministry pays, not the patient.
Ministry pays: $0.4575 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02400022)
Source record
DIN 02400022: Teva-Capecitabine
Raw flags: sec3=Y
Item: 100000136; group id 149; item number 0252; lccId None; manufacturer id TEV
Source form: Tab; strength: 150mg
Recorded listing: General benefit
Source prices (unrounded): $0.4575; ministry $0.4575
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02400022
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88486
Interchangeable products
Ach-Capecitabine · DIN 02426757 · $0.4575
Capecitabine · DIN 02514982 · $0.4575
Capecitabine · DIN 02519879 · $0.4575
Sandoz Capecitabine · DIN 02421917 · $0.4575
Taro-Capecitabine · DIN 02457490 · $0.4575
Xeloda · DIN 02238453 · $0.4575
Shortage status: resolved shortage (ended April 30, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02400022
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since March 16, 2022 — choose a marketed DIN from the same-category list.
Xeloda · DIN 02238453 · 150 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2022-12-07 — choose a marketed DIN from the same-category list.Discontinued December 7, 2022 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-12-07 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-12-07 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Xeloda · DIN 02238453
Manufacturer: Hoffmann-La Roche Limited; listing date 2001-06-07
Health Canada: Cancelled post market since 2022-12-07 · brand XELODA · ATC L01BC06 CAPECITABINE · form Tablet · route Oral · ingredients CAPECITABINE 150 MG · company Cheplapharm arzneimittel gmbh · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMinistry pays: $0.4575 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02238453)
Source record
DIN 02238453: Xeloda
Raw flags: sec3=Y
Item: 100000136; group id 149; item number 0252; lccId None; manufacturer id HLR
Source form: Tab; strength: 150mg
Recorded listing: General benefit
Source prices (unrounded): $1.9478; ministry $0.4575
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02238453
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61873
Interchangeable products
Ach-Capecitabine · DIN 02426757 · $0.4575
Capecitabine · DIN 02514982 · $0.4575
Capecitabine · DIN 02519879 · $0.4575
Sandoz Capecitabine · DIN 02421917 · $0.4575
Taro-Capecitabine · DIN 02457490 · $0.4575
Teva-Capecitabine · DIN 02400022 · $0.4575
Shortage status: discontinued (November 30, 2022, reported by CHEPLAPHARM ARZNEIMITTEL GMBH); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02238453
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since December 7, 2022 — choose a marketed DIN from the same-category list.
Teva-Capecitabine · DIN 02400030 · 500 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2022-03-16 — choose a marketed DIN from the same-category list.Discontinued March 16, 2022 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-03-16 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-03-16 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Capecitabine · DIN 02400030
Manufacturer: Teva Canada Limited; listing date 2013-10-31
Health Canada: Cancelled post market since 2022-03-16 · brand TEVA-CAPECITABINE · ATC L01BC06 CAPECITABINE · form Tablet · route Oral · ingredients CAPECITABINE 500 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Capecitabine: Formulary list price $1.53 per unit (the source does not state the unit; exact figure $1.5250). What the ministry pays, not the patient.
Ministry pays: $1.5250 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02400030)
Source record
DIN 02400030: Teva-Capecitabine
Raw flags: sec3=Y
Item: 100000137; group id 149; item number 0253; lccId None; manufacturer id TEV
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $1.5250; ministry $1.5250
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02400030
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88487
Interchangeable products
Ach-Capecitabine · DIN 02426765 · $1.5250
Capecitabine · DIN 02514990 · $1.5250
Capecitabine · DIN 02519887 · $1.5250
Mint-Capecitabine · DIN 02508028 · $1.5250
Sandoz Capecitabine · DIN 02421925 · $1.5250
Taro-Capecitabine · DIN 02457504 · $1.5250
Xeloda · DIN 02238454 · $1.5250
Shortage status: resolved shortage (ended May 17, 2017); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02400030
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since March 16, 2022 — choose a marketed DIN from the same-category list.
Xeloda · DIN 02238454 · 500 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2022-12-07 — choose a marketed DIN from the same-category list.Discontinued December 7, 2022 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-12-07 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-12-07 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Xeloda · DIN 02238454
Manufacturer: Hoffmann-La Roche Limited; listing date 2001-06-07
Health Canada: Cancelled post market since 2022-12-07 · brand XELODA · ATC L01BC06 CAPECITABINE · form Tablet · route Oral · ingredients CAPECITABINE 500 MG · company Cheplapharm arzneimittel gmbh · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMinistry pays: $1.5250 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02238454)
Source record
DIN 02238454: Xeloda
Raw flags: sec3=Y
Item: 100000137; group id 149; item number 0253; lccId None; manufacturer id HLR
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $6.4933; ministry $1.5250
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02238454
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61874
Interchangeable products
Ach-Capecitabine · DIN 02426765 · $1.5250
Capecitabine · DIN 02514990 · $1.5250
Capecitabine · DIN 02519887 · $1.5250
Mint-Capecitabine · DIN 02508028 · $1.5250
Sandoz Capecitabine · DIN 02421925 · $1.5250
Taro-Capecitabine · DIN 02457504 · $1.5250
Teva-Capecitabine · DIN 02400030 · $1.5250
Shortage status: discontinued (November 30, 2022, reported by CHEPLAPHARM ARZNEIMITTEL GMBH); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02238454
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since December 7, 2022 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (L01B, L01BC): coverage varies; not interchangeable
- Fluorouracil + salicylic acid (Actikerall): general benefit
- Mercaptopurine (Purinethol): general benefit
- Methotrexate (Methotrexate Sodium): general benefit, not a benefit
- Thioguanine (Lanvis): general benefit
- Fludarabine (Fludara): limited Use 424, 379
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered
Matched class: 10:00 ANTINEOPLASTIC AGENTS
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE
Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE
10:00 ANTINEOPLASTIC AGENTS
· 1 products · General benefit · strengths: 0.5% w/w & 10% w/w · Top Sol
· 2 products · General benefit · strengths: 50mg · Tab
· 34 products · General benefit (29), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 20mg/2mL, 50mg/2mL, 10mg/0.2mL, 12.5mg/0.25mL, 15mg/0.3mL, 17.5mg/0.35mL, 20mg/0.4mL, 22.5mg/0.45mL, 25mg/0.5mL, 2.5mg, 10mg · Inj Sol-2mL Pk, Inj Sol-Pref Syr, Tab
· 1 products · General benefit · strengths: 40mg · Tab
· 1 products ·
Limited Use, codes 424, 379 · strengths: 10mg · Tab
· 18 products · General benefit · strengths: 250mg, 500mg · Tab
· 1 products · General benefit · strengths: 50mg · Cap
· 18 products · General benefit · strengths: 1mg · Tab
· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab
· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk
· 1 products · General benefit · strengths: 2mg · Tab
· 1 products · General benefit · strengths: 2mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 10:00
and 34 more
Full class listing
Related classes:
Same formulary class, not same indication: class membership alone does not establish equivalent uses.